Clinical trial
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by…
NCT00365417 · NSABP Foundation Inc, Other · Completed
Key facts
| NCT number | NCT00365417 |
|---|---|
| Title | Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer |
| Official title | A Phase II Clinical Trial of Bevacizumab Beginning Concurrently With a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy Followed by Postoperative Bevacizumab Alone for Women With Locally Advanced Breast Cancer |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | Genentech, Inc. Industry Hoffmann-La Roche International Drug Development Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Doxorubicin, Cyclophosphamide, Capecitabine, Docetaxel |
| Enrollment | 45 |
| Start date | Aug 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Nov 1, 2009 |
| First posted | Aug 17, 2006 |
| Last update posted | Apr 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: